BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ren C, Ren J, Tian Z, Du Y, Hao Z, Zhang Z, Fang W, Li F, Zhang S, Hsu B, Huo L. Assessment of cardiac amyloidosis with 99mTc-pyrophosphate (PYP) quantitative SPECT. EJNMMI Phys 2021;8:3. [PMID: 33411102 DOI: 10.1186/s40658-020-00342-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zanwar S, Gertz MA, Muchtar E. Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment. J Natl Compr Canc Netw 2023;21:83-90. [PMID: 36630897 DOI: 10.6004/jnccn.2022.7077] [Reference Citation Analysis]
2 Fu C, Wang X, Cao X, Xu L, Liu W, Pi J, Wang B, Chen W. The Clinical Characteristics of Immunoglobulin Light Chain Amyloidosis in the Chinese Population: A Systematic Scoping Review. Hemato 2022;4:12-25. [DOI: 10.3390/hemato4010002] [Reference Citation Analysis]
3 Takata K, Shibutani N, Horita H. [Utility of the Method for Calculating the Heart to Contralateral Ratio for Cardiac Amyloidosis by Using Ray-summation Images in (99m)Tc-pyrophosphate Scintigraphy]. Nihon Hoshasen Gijutsu Gakkai Zasshi 2022;78:1399-405. [PMID: 36288937 DOI: 10.6009/jjrt.2022-1297] [Reference Citation Analysis]
4 Dickson JC, Armstrong IS, Gabiña PM, Denis-bacelar AM, Krizsan AK, Gear JM, Van den Wyngaert T, de Geus-oei L, Herrmann K. EANM practice guideline for quantitative SPECT-CT. Eur J Nucl Med Mol Imaging 2022. [DOI: 10.1007/s00259-022-06028-9] [Reference Citation Analysis]
5 Miller RJH, Fine N. Quantifying is believing: Techniques for evaluating transthyretin cardiac amyloidosis burden for expanded clinical applications. J Nucl Cardiol 2022;29:3111-4. [PMID: 34921352 DOI: 10.1007/s12350-021-02880-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Matsuda N, Otsuka H, Otani T, Azane S, Kunikane Y, Otomi Y, Ueki Y, Kubota M, Amano M, Yagi S, Sata M, Harada M. New quantitative indices of cardiac amyloidosis with 99mTc-pyrophosphate scintigraphy. Jpn J Radiol 2022. [DOI: 10.1007/s11604-022-01364-0] [Reference Citation Analysis]
7 Bae S, Gil J, Paeng JC, Park EA, Lee SP, Choi H, Kang KW, Cheon GJ, Lee DS. Reliability and feasibility of visual grading systems and quantitative indexes on [(99m)Tc]Tc-DPD imaging for cardiac amyloidosis. Sci Rep 2022;12:17271. [PMID: 36241893 DOI: 10.1038/s41598-022-21603-8] [Reference Citation Analysis]
8 Sperry BW, Bateman TM, Akin EA, Bravo PE, Chen W, Dilsizian V, Hyafil F, Khor YM, Miller RJH, Slart RHJA, Slomka P, Verberne H, Miller EJ, Liu C. Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM. J Nucl Cardiol 2022. [PMID: 35864433 DOI: 10.1007/s12350-022-02985-8] [Reference Citation Analysis]
9 Benz DC, Dorbala S, Pazhenkottil AP. Quantifying the burden of cardiac amyloid: The future is about numbers! J Nucl Cardiol . [DOI: 10.1007/s12350-022-03011-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Yaros K, Eksi B, Chandra A, Agusala K, Lehmann LH, Zaha Vlad G. Cardio-oncology imaging tools at the translational interface. Journal of Molecular and Cellular Cardiology 2022. [DOI: 10.1016/j.yjmcc.2022.03.012] [Reference Citation Analysis]
11 Ogasawara K, Shiraishi S, Tsuda N, Sakamoto F, Oda S, Takashio S, Tsujita K, Hirai T. Usefulness of quantitative 99mTc-pyrophosphate SPECT/CT for predicting the prognosis of patients with wild-type transthyretin cardiac amyloidosis. Jpn J Radiol 2022. [PMID: 34973114 DOI: 10.1007/s11604-021-01221-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhu Y, Pan R, Peng D, Dong Q, Zhu X. Pitfalls of the Semi-Quantitative Analyzing 99mTc-Pyrophosphate Planar Images for Diagnosing Transthyretin Cardiac Amyloidosis: A Possible Solution. Diagnostics 2022;12:94. [DOI: 10.3390/diagnostics12010094] [Reference Citation Analysis]
13 Fu C, Wang X, Cao X, Xu L, Liu W, Pi J, Wang B, Chen W. The Clinical Characteristics of Immunoglobulin Light Chain Amyloidosis in the Chinese Population: A Systematic Scoping Review (Preprint).. [DOI: 10.2196/preprints.35359] [Reference Citation Analysis]
14 Ruan D, Sun L. Diagnostic efficacy of bone scintigraphy in transthyretin cardiac amyloidosis: an updated systematic review and Bayesian bivariate meta-analysis. Clin Transl Imaging. [DOI: 10.1007/s40336-021-00471-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Huang YH, Lin YH, Yen RF, Hou CJ, Wang SY, Tsai SC, Ho KC, Lin MH, Tsao CH, Chang CY, Huang JL, Cheng MF, Wu YW. 2021 Advocacy Statements for the Role of 99mTc-Pyrophosphate Scintigraphy in the Diagnosis of Transthyretin Cardiac Amyloidosis: A Report of the Taiwan Society of Cardiology and the Society of Nuclear Medicine of the Republic of China. Acta Cardiol Sin 2021;37:221-31. [PMID: 33976505 DOI: 10.6515/ACS.202105_37(3).20210420A] [Reference Citation Analysis]